Pancreatic Cancer Summit Priorities Update

Monday 29/10/2018 

  • Victorian Tumour Summits has produced the Pancreatic Cancer 2017 Summit Prioritised Variations video. This video is a resource for clinicians, by clinicians. Featuring Drs Charles Pilgrim and Belinda Lee. 


Pancreatic Cancer Summit in pictures


What was the Pancreatic Cancer Summit?

Diagnosis and treatment of pancreatic cancer has a significant physical and emotional impact on patients and their loved ones.  The Victorian Tumour Summits are clinician led forums seeking to identify unwarranted variations in tumour based clinical practice and cancer outcomes that could be addressed through state-wide action. Seventy stakeholders from across Victoria gathered on November 24 to discuss variations in care and identify opportunities for improvement.

Watch the presentation by Professor Robert Thomas:


Watch the presentation by Ms Kathryn Whitfield:


Watch the data presentation by Dr Charles Pilgrim:

Watch a summary of the day by Dr Charles Pilgrim:


What is Data Telling Us?

  • One-year relative survival increased from 27% to 34% between 2011-15.
  • Post-operative mortality is low by international standards: 2.1% (30 days); 2.7% (90 days); 19.7% (1-year).
  • A decrease in the number of Victorian hospitals conducting low volumes of pancreatic resections (1-3 per year) from 10 to 4 between the 2014/15 and 2016/17 financial years.
  • Only 5% of patients who had curative surgery for non-metastatic pancreatic ductal adenocarcinoma had neoadjuvant therapy.
  • 23% of patients who had curative surgery for non-metastatic pancreatic ductal adenocarcinoma did not have adjuvant therapy.
  • The state-wide average for documented multidisciplinary meeting discussion was 70% in 2013-15.
  • 75% of deaths for pancreatic cancer occurred during a hospital admission.

Post-Summit Update

Of these variations, several were prioritised for further investigation and action:

  1. Adjuvant therapy – 23% of patients who had curative surgery for non-metastatic pancreatic ductal adenocarcinoma did not have adjuvant therapy.
  2. Multidisciplinary meetings – 70% was the state average for multidisciplinary meeting discussion in the years 2013-2015.
  3. Palliative care – 75% of pancreatic cancer deaths occur in hospital.

The clinical working party reconvened in March 2018 to revisit outcomes of the summit discussion and review additional evidence of prioritised variations.  

Further work has occurred to analyse cases who did not receive adjuvant therapy. It appears patients who underwent surgery in the NEMICS & BSWRICS regions were less likely to receive adjuvant therapy. Compared to patients who did receive therapy, these patients were:

  • Older
  • Spent a greater number of hours in ICU during their surgery episode
  • Had a longer length of stay during their surgery episode
  • Had a higher 30- and 90-day mortality rate following surgery

Of these patients, 26% were less than 70 years of age, had no known comorbidities and were alive 90 days following surgery.

In relation to multidisciplinary meetings, the working party highlighted the need for up-to-date data to determine the cause of the discussion rate for pancreatic cancer patients.  The group recognised it is likely that stage IV patients are not discussed due to limited multidisciplinary meeting resources.  

Data on hospital deaths was considered to indicate possible issues with the current usage of state-wide palliative care services.  Based on palliative care clinical feedback from studies on other cancer types, timeliness of contact with palliative care services could have a positive outcome on reducing the percentage of patients with pancreatic cancer dying in hospital. A focus for action has yet to be determined.

As of 2018 most clinical teams caring for pancreatic cancer patients in Victoria are aware of the variations in care prioritised at the summit, as well as the upcoming optimal cancer care pathways implementation program.  If you have had an opportunity to discuss how these variations relate to the care you provide and how you would create a measurable investigation, contact on (03) 9496 3455.

What is Pancare?

The Pancare Foundation was established to be the long-standing voice of those affected by pancreatic, liver, biliary, oesophageal and stomach cancers. Pancare work to save and improve lives through public awareness, support, education and research.

Pancare has produced a series of guides for patients and carers as they undergo their cancer journey:

  • Pancreatic Cancer Patient Handbook - provides a general introduction to pancreatic cancer, information on tests and investigations that help confirm a diagnosis and provides an overview of possible treatment options and the wider impact of the diagnosis.
  • Pancreatic Cancer Dietary Handbook - highlights important information about managing your diet if you have or have had pancreatic cancer.

Download patient and carer handbooks here

For hard copies contact Pancare on 1300 881 698 or email


Pancreatic Cancer Summit working party


Dr Rob Blum
Prof Christopher Christophi
Mr Dan Croagh
Mr David Deutscher
Mr Adrian Fox
A/Prof Peter Gibbs
Mr George Kalogeropoulos
Dr Richard Khor
A/Prof Brian Le
Dr Belinda Lee
Mr Mehrdad Nikfarjam
Mr Charles Pilgrim
Dr Babak Tamjid
A/Prof Niall Tebbutt
A/Prof Ben Thomson
A/Prof Valery Usatoff
Prof John Zalcberg


Project team


Ms Mirela Matthews
Ms Amy Sutherland
Ms Megan Dendle
Mr Luc te Marvelde
Ms Ella Stuart
print text size increase